Complement receptor 1

(Redirected from Knops antigen system)
Jump to: navigation, search
Complement component (3b/4b) receptor 1 (Knops blood group)
PBB Protein CR1 image.jpg
PDB rendering based on 1gkg.
Identifiers
Symbol(s) CR1; C3BR; CD35; KN
External IDs OMIM: 120620 Homologene55474
RNA expression pattern

PBB GE CR1 206244 at tn.png

PBB GE CR1 208488 s at tn.png

PBB GE CR1 217552 x at tn.png

More reference expression data

Orthologs
Human Mouse
Entrez 1378 na
Ensembl ENSG00000203710 na
Uniprot P17927 na
Refseq XM_001126036 (mRNA)
XP_001126036 (protein)
na (mRNA)
na (protein)
Location Chr 1: 205.74 - 205.88 Mb na
Pubmed search [1] na

WikiDoc Resources for Complement receptor 1

Articles

Most recent articles on Complement receptor 1

Most cited articles on Complement receptor 1

Review articles on Complement receptor 1

Articles on Complement receptor 1 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Complement receptor 1

Images of Complement receptor 1

Photos of Complement receptor 1

Podcasts & MP3s on Complement receptor 1

Videos on Complement receptor 1

Evidence Based Medicine

Cochrane Collaboration on Complement receptor 1

Bandolier on Complement receptor 1

TRIP on Complement receptor 1

Clinical Trials

Ongoing Trials on Complement receptor 1 at Clinical Trials.gov

Trial results on Complement receptor 1

Clinical Trials on Complement receptor 1 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Complement receptor 1

NICE Guidance on Complement receptor 1

NHS PRODIGY Guidance

FDA on Complement receptor 1

CDC on Complement receptor 1

Books

Books on Complement receptor 1

News

Complement receptor 1 in the news

Be alerted to news on Complement receptor 1

News trends on Complement receptor 1

Commentary

Blogs on Complement receptor 1

Definitions

Definitions of Complement receptor 1

Patient Resources / Community

Patient resources on Complement receptor 1

Discussion groups on Complement receptor 1

Patient Handouts on Complement receptor 1

Directions to Hospitals Treating Complement receptor 1

Risk calculators and risk factors for Complement receptor 1

Healthcare Provider Resources

Symptoms of Complement receptor 1

Causes & Risk Factors for Complement receptor 1

Diagnostic studies for Complement receptor 1

Treatment of Complement receptor 1

Continuing Medical Education (CME)

CME Programs on Complement receptor 1

International

Complement receptor 1 en Espanol

Complement receptor 1 en Francais

Business

Complement receptor 1 in the Marketplace

Patents on Complement receptor 1

Experimental / Informatics

List of terms related to Complement receptor 1

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]


Overview

In primates, erythrocyte complement receptor 1 (CR1, also known as CD35, C3b/C4b receptor and immune adherence receptor) serves as the main system for processing and clearance of complement opsonized immune complexes. It has been shown that CR1 can act as a negative regulator of the complement cascade, mediate immune adherence and phagocytosis and inhibit both the classic and alternative pathways. The number of CR1 molecules decreases with aging of erythrocytes in normal individuals and is also decreased in pathological conditions such as systemic lupus erythematosus (SLE), HIV infection, some haemolytic anaemias and other conditions featuring immune complexes.

1q32 region

In humans, the CR1 gene is located at on the long arm of chromosome 1 at band 32 (1q32) and lies within a complex of immunoregulatory genes. In 5’-3’ order the genes in this region are: membrane cofactor protein - CR1- complement receptor type 2 - decay-accelerating factor - C4-binding protein.

Factor H, another immunoregulatory protein, also maps to this location.

Forms

The most common form of the CR1 gene (CR1*1) is composed of 38 exons spanning 133kb encoding a protein of 2039 amino acids and has a predicted molecular weight of 220 kDa. Large insertions and deletions have given rise to four structurally variant genes and some alleles may extend up to 160 kb and 9 additional exons. The transcription start site has been mapped to 111 bp upstream of the translation initiation codon ATG and there is another possible start site 29 bp further upstream. The promoter region lacks a distinct TATA box sequence. The gene is expressed principally on erythrocytes, monocytes, neutrophils and B cells but is also present on some T lymphocytes, mast cells and glomerular podocytes.

The mean number of complement receptor 1 (CR1) molecules on erythrocytes in normal individuals lies within the range of 100-1000 molecules per cell. Two codominant alleles exist - one controlling high and the other low expression. Homozygotes differ by a factor of 10-20: heterozygotes typically have 500-600 copies per erythrocyte. These two alleles appear to have originated before the divergence of the European and African populations.

Structure

The encoded protein has a 47 amino acid signal peptide, an extracellular domain of 1930 residues, a 25 residue transmembrane domain and a 43 amino acid C terminal cytoplasmic region. The leader sequence and 5'-untranslated region are contained in one exon. The large extracellular domain of CR1, which has 25 potential N-glycosylation sites, can be divided into 30 short consensus repeats (SCRs) (also known as complement control protein repeats (CCPs) or sushi domains), each having 60 to 70 amino acids. The sequence homology between SCRs ranges between 60 to 99 percent. The transmembrane region is encoded by 2 exons and the cytoplasmic domain and the 3'-untranslated regions are coded for by two separate exons.

The 30 or so SCRs are further grouped into four longer regions termed long homologous repeats (LHRs) each encoding approximately 45 kDa of protein and designated LHR-A, -B, -C, and -D. The first three have seven SCRs while LHR-D has 9 or more. Each LHR is composed of 8 exons and within an LHR, SCR 1, 5, and 7 are each encoded by a single exon, SCR 2 and 6 are each encoded by 2 exons, and a single exon codes for SCR 3 and 4. The LHR seem to have arisen as a result of unequal crossing over and the event that gave rise to LHR-B seems to have occurred within the fourth exon of either LHR-A or –C. To date the atomic structure have been solved for SCRs 15-16, 16 & 16-17.

Alleles

Four alleles are known with predicted protein molecular weights of 190 kDa, 220 kDa, 250 kDa and 280kDa are known. Multiple size variants (55kDa-220kDa) are also found among non-human primates and a partial amino-terminal duplication (CR1-like gene) that encodes the short (55kDa-70kDa) forms expressed on non human erythrocytes. These short CR1 forms, some of which are glycosylphosphatidylinositol (GPI) anchored, are expressed on erythrocytes and the 220kDa molecular weight CR1 form is expressed on monocytes. The gene including the repeats is highly conserved in primates possibly because of the ability of the repeats to bind complement. LHR-A binds preferentially to the complement component C4b: LHR-B and LHR-C bind to C3b and also, albeit with a lower affinity, to C4b. Curiously the human CR1 gene appears to have an unusual protein conformation but the significance of this finding is not clear.

Rosetting

Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) interacts with uninfected erythrocytes. This 'stickiness', known as rosetting, is believed to be a strategy used by the parasite to remain sequestered in the microvasculature to avoid destruction in the spleen and liver. Erythrocyte rosetting causes obstruction of the blood flow in microcapillaries. There is a direct interaction between PfEMP1 and a functional site of complement receptor type 1 on uninfected erythrocytes.

Role in blood Groups

The Knops antigen was the 25th blood group system recognized and consists of the single antigen York (Yk) a with the following allelic pairs:

  • Knops (Kn) a and b
  • McCoy (McC) a and b
  • Swain-Langley (Sl) 1 and 2

The antigen is known to lie within the CR1 protein repeats and was first described in 1970 in a 37-year-old Caucasian woman. Racial differences exist in the frequency of these antigens: 98.5% and 96.7% of American Caucasians and Africans respectively are positive for McC(a). 36% of a Mali population were Kn(a) and 14% of exhibited the null (or Helgeson) phenotype compared with only 1% in the American population. The frequencies of McC (b) and Sl (2) are higher in Africans compared with Europeans and while the frequency of McC (b) was similar between Africans from the USA or Mali, the Sl (b) phenotype is significantly more common in Mali - 39% and 65% respectively. In Gambia the Sl (2)/McC(b) phenotype appears to have been positively selected - presumably due to malaria. 80% of Papua New Guineans have the Helgeson phenotype and case control studies suggest this phenotype has a protective effect against severe malaria.

References

Further reading

  • Ahearn JM, Fearon DT (1989). "Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).". Adv. Immunol. 46: 183–219. PMID 2551147. 
  • Wong WW, Farrell SA (1991). "Proposed structure of the F' allotype of human CR1. Loss of a C3b binding site may be associated with altered function.". J. Immunol. 146 (2): 656–62. PMID 1670949. 
  • Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT (1991). "Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex.". J. Exp. Med. 173 (5): 1083–9. PMID 1708808. doi:10.1084/jem.173.5.1083. 
  • Moulds JM, Nickells MW, Moulds JJ; et al. (1991). "The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera.". J. Exp. Med. 173 (5): 1159–63. PMID 1708809. doi:10.1084/jem.173.5.1159. 
  • Rao N, Ferguson DJ, Lee SF, Telen MJ (1991). "Identification of human erythrocyte blood group antigens on the C3b/C4b receptor.". J. Immunol. 146 (10): 3502–7. PMID 1827486. 
  • Hourcade D, Miesner DR, Bee C; et al. (1990). "Duplication and divergence of the amino-terminal coding region of the complement receptor 1 (CR1) gene. An example of concerted (horizontal) evolution within a gene.". J. Biol. Chem. 265 (2): 974–80. PMID 2295627. 
  • Reynes M, Aubert JP, Cohen JH; et al. (1985). "Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.". J. Immunol. 135 (4): 2687–94. PMID 2411809. 
  • Hinglais N, Kazatchkine MD, Mandet C; et al. (1989). "Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study.". Lab. Invest. 61 (5): 509–14. PMID 2478758. 
  • Fearon DT, Klickstein LB, Wong WW; et al. (1989). "Immunoregulatory functions of complement: structural and functional studies of complement receptor type 1 (CR1; CD35) and type 2 (CR2; CD21).". Prog. Clin. Biol. Res. 297: 211–20. PMID 2531419. 
  • Wong WW, Cahill JM, Rosen MD; et al. (1989). "Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele.". J. Exp. Med. 169 (3): 847–63. PMID 2564414. doi:10.1084/jem.169.3.847. 
  • Wong WW, Kennedy CA, Bonaccio ET; et al. (1986). "Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type I. Duplication of genomic sequences occurs in association with a high molecular mass receptor allotype.". J. Exp. Med. 164 (5): 1531–46. PMID 2877046. doi:10.1084/jem.164.5.1531. 
  • Wong WW, Klickstein LB, Smith JA; et al. (1985). "Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b.". Proc. Natl. Acad. Sci. U.S.A. 82 (22): 7711–5. PMID 2933745. doi:10.1073/pnas.82.22.7711. 
  • Klickstein LB, Wong WW, Smith JA; et al. (1987). "Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins.". J. Exp. Med. 165 (4): 1095–112. PMID 2951479. doi:10.1084/jem.165.4.1095. 
  • Moldenhauer F, David J, Fielder AH; et al. (1987). "Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus.". Arthritis Rheum. 30 (9): 961–6. PMID 2959289. doi:10.1002/art.1780300901. 
  • Hourcade D, Miesner DR, Atkinson JP, Holers VM (1988). "Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1.". J. Exp. Med. 168 (4): 1255–70. PMID 2971757. doi:10.1084/jem.168.4.1255. 
  • Klickstein LB, Bartow TJ, Miletic V; et al. (1988). "Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.". J. Exp. Med. 168 (5): 1699–717. PMID 2972794. doi:10.1084/jem.168.5.1699. 
  • Hing S, Day AJ, Linton SJ; et al. (1989). "Assignment of complement components C4 binding protein (C4BP) and factor H (FH) to human chromosome 1q, using cDNA probes.". Ann. Hum. Genet. 52 (Pt 2): 117–22. PMID 2977721. 
  • Fearon DT (1985). "Human complement receptors for C3b (CR1) and C3d (CR2).". J. Invest. Dermatol. 85 (1 Suppl): 53s–57s. PMID 2989379. doi:10.1111/1523-1747.ep12275473. 
  • Wilson JG, Murphy EE, Wong WW; et al. (1986). "Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes.". J. Exp. Med. 164 (1): 50–9. PMID 3014040. doi:10.1084/jem.164.1.50. 
</dl>

External links



Linked-in.jpg